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A b s t r a c t
Introduction: Atrial septal defect (ASD) is the most common congenital cardiac anomaly diagnosed in adults. It often remains 
asymptomatic until the fourth or fifth decade of life. Significant left-to-right interatrial shunting is associated with the risk of heart 
failure, pulmonary hypertension and atrial fibrillation. Percutaneous ASD closure is a recognized method of treatment.
Aim: To evaluate the clinical outcomes and physical capacity in patients undergoing transcatheter closure of ostium secundum ASD.
Material and methods: One hundred and twenty adult patients (75 females and 45 males) with a mean age of 43.1 ±13.3 
(17–78) years who underwent transcatheter device closure of ostium secundum ASD were analyzed. Clinical evaluation and trans-
thoracic color Doppler echocardiographic study were repeated in all patients before as well as 1 and 24 months after the procedure. 
To assess the physical capacity symptom-limited treadmill exercise tests with respiratory gas-exchange analysis were performed in 
all patients before the procedure and after 24 months of follow-up.
Results: The devices were successfully implanted in all patients. During 24 months of follow-up all patients showed significant 
clinical and spiroergometric improvement of exercise capacity, and a significant decrease of right heart chamber overload features 
on echocardiography.
Conclusions: Transcatheter closure of ASD in patients with significant shunt resulted in significant clinical and hemodynamic 
improvement regardless of the baseline functional class.
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Introduction
Atrial septal defect (ASD) is the most common con-
genital cardiac anomaly diagnosed in adults (22–25% of 
all cases). Atrial septal defect constitutes 7–11% of all 
cardiac defects and occurs twice as often in women [1, 2].
Atrial septal defect frequently remains asymptomat-
ic until the fourth or fifth decade of life, when patients 
start to complain of reduced exercise capacity, dyspnea, 
and nonspecific chest pain. Atrial fibrillation occurs in ap-
proximately 10–15% of patients and its incidence tends 
to increase with age [1, 3]. Pulmonary hypertension de-
velops in 10% of ASD patients, especially in the presence 
of relevant left-to-right shunt (pulmonary to systemic 
blood flow ratio ≥ 2 : 1).
Until the 1970s surgical management of ASDs had 
been the only treatment available. The first catheter occlu-
sion of ASD was performed by King and Mills in 1976 [4]. 
Since then there has been dynamic progress and refine-
ment of transcatheter closure techniques. In the 1990s 
several new devices were introduced, including the Sider-
is buttoned device, Das Angel Wings, ASDOS, CardioSeal, 
and Amplatzer Septal Occluder (first used by J. Masura in 
Bratislava in 1995 [5]). Over the last couple of years the use 
of CardioSeal and Amplatz devices has yielded the most 
promising results. At present the percutaneous method is 
an accepted treatment of ostium secundum ASDs.
Aim
The aim of this study was to explore hemodynam-
ic effects and clinical outcomes in patients undergoing 
transcatheter closure of ostium secundum ASDs based 
on self-collected data.
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Material and methods
We enrolled 120 consecutive adult patients with os-
tium secundum ASD in the study (75 females and 45 
males). All patients underwent transcatheter closure of 
ASD. The mean age of enrolled patients was 43.1 ±13.3 
(17–78) years.
The diagnosis of ASD was based on clinical exam-
ination and transthoracic echocardiography (TTE). The 
patients were qualified for the procedure depending on 
the results of transesophageal echocardiographic study 
(TEE). The diagnosis and feasibility were confirmed by 
heart catheterization directly before device implantation.
Principal qualification criteria for transcatheter closure 
were: single central ostium secundum ASD, maximal de-
fect diameter of 38 mm, minimal surrounding tissue mar-
gin of 5 mm, and hemodynamically significant left-to-right 
shunting (pulmonary to systemic blood flow ratio (Qp : Qs) 
> 1.5 : 1). Two patients were found to have two ASDs with 
localization allowing closure with a single device.
Devices were implanted in a typical way as described 
above. 
The procedures were performed under local anes-
thesia after oral premedication with lorazepam and an-
tiemetic administration. During the procedure every pa-
tient received an IV bolus of unfractionated heparin (UFH, 
100 U/kg) which was either continued as an IV drip up to 
12 h after ASD closure or exchanged for two SC injections of 
enoxaparin (1 mg/kg) every 12 h. In addition, for 6 months 
following the procedure patients received aspirin. 
Cardiac functional capacity assessment (according to 
New York Heart Association (NYHA) classification) and 
TTE studies were performed before the device implan-
tation, as well as at 1 and 24 months after ASD closure. 
Transthoracic echocardiograms were obtained using 
Toshiba Power Vision 6000 and Aloka 550 ultrasound 
machines (cardiac transducers with frequency range of 
2–3.7 MHz) according to the Standards of the Polish Car-
diac Society Section of Echocardiography. The TTE exam-
ination comprised evaluation of dimensions of cardiac 
chambers, valvular pathologies, pulmonary artery systol-
ic pressure (PASP) estimated by tricuspid regurgitation 
pressure gradient, and calculation of pulmonary (Qp) to 
systemic (Qs) blood flow ratio. Size of the right atrium 
(RA) was assessed in apical-four-chamber view by mea-
suring its short axis dimension in ventricular end-systole. 
The right ventricle (RV) analysis consisted of measuring 
its end-diastolic diameter in parasternal long-axis view 
using M-mode presentation. Post-procedural TTE study 
included evaluation of the aforementioned features, po-
sition of the occluder, possible residual interatrial shunt-
ing, and presence and degree of valvular regurgitations. 
In one case residual shunting was evaluated by TEE due 
to equivocal results of the TTE study.
As an integral part of comprehensive physical capac-
ity evaluation, clinical assessment and echocardiogra-
phy were complemented with cardiopulmonary exercise 
testing (CPET) performed prior to and 24 months after 
the procedure. The CPET was performed with the Sensor 
Medicus 229 system and Market type treadmill using the 
modified Bruce protocol. 
Maximal oxygen consumption (VO2max) was measured 
when oxygen uptake remained stable despite workload 
escalation. Normal VO
2max values were predicted accord-
ing to the Wasserman equation taking into account age, 
sex and weight of the patients. When achieved CPET re-
sults did not reach 85% of predicted normal values, de-
creased physical capacity was recognized. Peak oxygen 
consumption (VO
2peak) was estimated as an average of 
measurements taken during the last 30 s of exercise. The 
values were presented with respect to body weight in ki-
lograms (ml/kg/min) and as a  percentage of predicted 
normal VO
2max (VO2peak%N).
Anaerobic threshold (AT) was established according 
to Wasserman’s criteria by noninvasive gas exchange 
analysis. Other measured CPET parameters included: 
heart rate at rest (HR
rest), exercise duration (T), oxygen 
consumption at anaerobic threshold (VO
2AT), and several 
parameters at peak effort, i.e. maximal heart rate (HR
peak), 
peak oxygen consumption expressed both in ml/kg/min 
(VO
2peak) and as percentage of predicted normal VO2max 
(VO
2peak %N), ventilatory equivalent ratio for oxygen 
(VE/VO
2peak) and carbon dioxide (VE/VCO2peak), and partial 
pressure of carbon dioxide in expired air (PETCO
2peak).
Statistical analysis
SPSS software was used for statistical calculations. 
The c2 test was used for statistical analysis of the collect-
ed data. Qualitative variables were compared by Fisher’s 
exact test for contingency tables. Differences between 
groups were assessed with paired Student’s t-test. Multi-
ple comparison analysis was conducted with the analysis 
of variance (ANOVA) test.
Results
Baseline echocardiographic studies showed en-
largement of the right atrium (> 36 mm) and ventricle 
(> 25 mm) in 106 (88.3%) patients, and paradoxical sep-
tal motion in 72 (60%) individuals. Baseline mean PASP 
on cardiac catheterization was 30.7 ±8.7 (24–45) mm Hg, 
and mean Qp : Qs ratio was 1.8 (1.5–3.1). Mean ASD di-
ameter measured by TEE was 14.2 ±4.3 (7–24) mm, while 
the stretched diameter determined with a balloon sizing 
catheter was 16.2 ±5.9 (13–28) mm. 
The diameter of implanted devices ranged from 13 to 
32 mm (average: 21.6 ±6.9 mm).
During the first 24 h following the device closure there 
was a small, insignificant residual shunting on echocar-
diography in 4 (3.3%) patients which disappeared over 
a  30-day follow-up period. Multifactor analysis taking 
into account the degree of shunting before the procedure 
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and the size of the used occluders proved them unrelated 
to the residual leak. 
Paradoxical septal motion observed in 78 (65%) indi-
viduals prior to ASD closure normalized in all cases with-
in a month after the procedure (p < 0.0001).
During a  30-day follow-up RV diastolic diameter de-
creased by a mean of 5.0 ±3.4 (1.5–8) mm in 84 (70%) pa-
tients, while in 87 (72.5%) patients RA diameter decreased 
on average by 8.65 ±4.3 (2–20) mm. Moreover, 33 (27.5%) 
individuals presented a decrease of the left atrium dimen-
sion by 6.2 ±3.6 (1–18) mm on average. The TTE studies 
performed after 24 months mainly showed further reduc-
tion of RA size. In 88 (73.3%) cases the size of the right 
heart chambers returned to normal. The comparison of 
echocardiographic findings is depicted in Table I. 
Within 30 days of observation there were no remark-
able changes regarding physical capacity assessed by 
NYHA classification. On the other hand, after 24 months 
114 (95%) patients experienced improvement in NYHA 
class ≥ 1 (Table II). 
Before device implantation all patients underwent 
CPET, which confirmed impaired exercise tolerance in 
108 (90%) subjects. Mean VO
2max ranged from 19 to 27 
(22.5 ±7.9) ml/kg/min, and the average exercise dura-
tion was 12.0 ±5.9 (6–20) min. There was a significant 
improvement of physical capacity after 24 months fol-
lowing the procedure. Subsequent CPETs demonstrated 
longer exercise time, increased peak and maximal oxy-
gen consumption and lower VE/VCO
2peak values (Table III).
Spiroergometric parameters at anaerobic threshold 
(AT) before and after ASD closure differed considerably. 
At baseline average time to AT was 420 ±165 s with 
mean oxygen consumption of 14.1 ±3.8 ml/kg/min. Fol-
lowing device implantation patients reached AT on aver-
age after 501 ±192 s with oxygen uptake of 16.1 ±9.2 ml/
kg/min (Table IV).
Measured VO
2max values differed significantly before 
and after ASD closure depending on the physical capac-
ity. Mean VO
2max achieved by patients in NYHA class I–II 
was considerably higher than those in NYHA class III 
(24.3 ±7.9 vs. 21.6 ±5.5; p < 0.002). Within 24 months of 
observation there was improvement in VO
2max regardless 
of the baseline NYHA functional class (Table V). 
Moreover, there were statistically significant differenc-
es in spiroergometric results between patients with nor-
mal (< 30 mm Hg) and elevated (> 30 mm Hg) right ven-
tricular systolic pressure (RVSP). The group with normal 
RVSP had higher VO
2max and VO2AT levels, and longer time 
to AT point both before and after ASD closure (Table VI). 
Table I. Dimensions of the right heart chambers 
before and after ASD closure
Variable Right ventricle – 
PLAX, M-mode
[mm]
Right atrium – A4C, 
lateromedial  
diameter [mm]
Before procedure 32.3 ±8.2 46 ±6.4
1 month after  
the procedure
24.0 ±3.3 41 ±4.6
24 months after 
the procedure
23.0 ±2.8 37 ±4.3
P-value (before 
vs. 1 month after 
the procedure)
< 0.001 < 0.01
P-value (before 
vs. 24 months af-
ter the procedure)
< 0.001 < 0.002
ASD – atrial septal defect, PLAX – parasternal long-axis view, A4C – apical 
four-chamber view.
Table II. Functional capacity of patients according to NYHA classification
Variable Before the procedure  
(n = 120)
1 month after the procedure  
(n = 120)
24 months after the procedure 
(n = 120)
No heart failure symptoms 0 (0%) 0 (0%) 87 (72.5%)
NYHA I 48 (40%) 64 (53.3%) 33 (27.5%)
NYHA II 53 (44.2%) 55 (45.8%) 0 (0%)
NYHA III 19 (15.8%) 1 (0.8%) 0 (0%)
NYHA IV 0 (0%) 0 (0%) 0 (0%)
NYHA – New York Heart Association.
Table III. Physical capacity assessed by cardiopulmonary exercise test
Parameter Before the procedure 24 months after the procedure P-value
Exercise duration [min] 12.5 ±5.4 (8–21) 19.5 ±7.4 (11–25) < 0.0001
VO
2max
 [ml/kg/min] 22.5 ±7.3 (18–27) 30.5 ±10.4 (24–34) < 0.0001
Peak VO
2
% 77.5 ±12.4 (70–81) 86.7 ±11.2 (76–90) < 0.0002
VE/VCO
2
 slope 26.9 ±7.9 (24–33.1) 24.1 ±6.8 (25–8.1) < 0.003
VO
2max 
– maximal oxygen consumption, peak VO
2
% – peak oxygen consumption, VE/VCO
2 
slope – minute ventilation/carbon dioxide production slope.
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However, there were no notable differences regarding 
the extent of improvement of CPET results against RVSP 
values. 
Spiroergometric parameters were also analyzed ac-
cording to the age of the subjects. The patients were sub-
divided into two groups: group I  comprised individuals 
aged ≤ 40 years (68, 56.7%), and group II comprised 52 
individuals aged 41–65 years (43.3%). The mean VO
2max 
increase in group I was higher and equaled 8.4 ±6.2 (3–
11) ml/kg/min, whereas in group II it was 3.0 ±2.3 (2–6.1) 
(p < 0.001). General excercise duration icreased from 
baseline 12.5 ±5.4 (8–21) min to 19.5 ±7.4 (11–25) min 
24 months after the procedure (p < 0.0001) (Table III).
Discussion
Almost half a century has passed since the first tran-
scatheter ASD occlusion. Nevertheless, the literature 
provides discrepant opinions regarding the controversial 
subject of ASD closure in adults with mild or no clinical 
symptoms. Some authors call into question the benefits 
of such a procedure, emphasizing its irrelevant effect on 
the lifespan and quality of life [6]. On the other hand, 
data published in 1970 by Campbell et al. hinted at sig-
nificantly lower life expectancy in patients with signifi-
cant interatrial shunting [1]. Within the analyzed popula-
tion with hemodynamically relevant ASD only 10–15% of 
patients lived past 60 years of age despite being asymp-
tomatic during the first decades of life. At present, the 
majority of opinions advocate ASD closure in the case 
of relevant left-to-right shunt despite the lack of clinical 
symptoms [7, 8].
In our experience the results of transcatheter ASD 
device closure are encouraging. The fact that the device 
implantation was successful in all patients enrolled in 
the study indicates that with proper selection of candi-
dates and careful qualification the procedure is safe and 
effective. 
In all cases the procedure was performed under local 
anesthesia preceded by mild premedication. Converse-
ly, most of the cited authors used general anesthesia 
[9, 10]. From our experience the majority of patients com-
ply well during peri-procedural TEE, and avoiding general 
anesthesia adds to simplification and shorter total time 
of the procedure.
According to the available literature residual shunting 
is observed in 1–4% of patients during 3–4 months of ob-
servation and tends to disappear within a year after device 
implantation [7, 8]. Our study corroborated these observa-
Table IV. Spiroergometric parameters at the point of the anaerobic threshold
Parameter Before the procedure 24 months after the procedure P-value
Time to AT [s] 420 ±165 501 ±192 < 0.001
VO
2





) 43.0 ±8.1 50.0 ±9.9 < 0.001
AT – anaerobic threshold, VO
2
AT – oxygen consumption at anaerobic threshold, VO
2
AT% – oxygen consumption at anaerobic threshold as percentage of maximal 
oxygen consumption.
Table V. Maximal oxygen uptake according to NYHA functional class
NYHA class before  
the procedure
VO2max before the procedure 
[ml/kg/min]
VO2max 24 months after the 
procedure [ml/kg/min]
P-value
NYHA I 25.3 ±6.2 31.0 ±8.7 < 0.002
NYHA II 23.3 ±4.5 29.1 ±4.2 < 0.002
NYHA III 21.6 ±5.5 26.4 ±5.3 < 0.001
NYHA – New York Heart Association, VO
2max
 – maximal oxygen consumption.
Table VI. Spiroergometric results depending on estimated right ventricular systolic pressure
Parameter Before the procedure 24 months after the procedure
RVSP < 30 mm Hg RVSP > 30 mm Hg P-value RVSP < 30 mm Hg RVSP > 30 mm Hg P-value
AT time [s] 489 ±210 390 ±199 < 0.0001 590 ±230 470 ±187 < 0.001
VO
2





) 46.0 ±4.1 41.0 ±7.9 < 0.01 51.0 ±5.1 47 ±8.9 < 0.001
VO
2max
 [ml/kg/min] 24 ±7.1 21 ±10.4 < 0.0001 33 ±9.1 27 ±9.4 < 0.0001
RVSP – right ventricular systolic pressure, AT – anaerobic threshold, VO
2
AT – oxygen consumption at anaerobic threshold, VO
2
AT% – oxygen consumption at anaer-
obic threshold as percentage of maximal oxygen consumption, VO
2max
 – maximal oxygen consumption.
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tions – post-procedural residual shunting was detected in 
6 (5%) cases and receded in the subsequent 30 days.
We established that significant improvement of phys-
ical capacity, expressed by longer exercise duration and 
higher maximal oxygen consumption, was already evi-
dent after 24 months following percutaneous ASD oc-
clusion. In contrast, Helber et al. following up patients 
after surgical ASD closure observed an increase in VO2max 
only after 10 years, and no notable effects within the first 
4 months [8]. The authors explained this delayed im-
provement by operative trauma and lack of exercise due 
to sedentary lifestyle immediately after surgery – which 
is not a factor in the case of the transcatheter techniques. 
In our group even patients with initially normal or 
mildly impaired physical capacity (NYHA I–II class) pre-
sented clinical improvement and achieved better results 
in CPET later on. These data prove ASD closure in asymp-
tomatic patients to be both justifiable and beneficial. 
Brochu et al., likewise, studied a group of ASD patients 
aged on average 49.4 (19–76) years, either with mild or 
without clinical symptoms (NYHA I–II) before and after 
device closure [11]. They observed significant improve-
ment of physical capacity as well, despite its slight base-
line impairment. 
In our study exercise capacity after ASD closure 
tended to increase remarkably in patients younger than 
40 years. These observations are borne out by other au-
thors such as Brochu et al., who established that CPET 
parameters after 6 months following the procedure were 
significantly better in younger individuals [11]. 
Although subjective clinical improvement is reported 
only after 24 months of observation, objective echocar-
diographic features of right heart volume overload (i.e. 
decrease of RA and RV size, normalization of intraventric-
ular septal motion) decreased already after a  month. In 
most patients the size of right heart chambers returned 
to normal in a 24-month follow-up, which was consistent 
with the findings of Zhong-Dong et al. [12]. Furthermore, 
Dhillon et al. observed improvement of right ventricular 
systolic and diastolic function 6–12-months after ASD clo-
sure [13–15]. 
To sum up, there is beyond doubt a need for extend-
ed follow-up as well as determination of long-term out-
comes of transcatheter ASD closure and possible adverse 
effects associated with the use of large occluders. 
Conclusions
Transcatheter ostium secundum ASD closure is a safe 
and effective method which can be performed without 
general anesthesia. Improvement of hemodynamic pa-
rameters was observed already after 1 month following 
the procedure (decrease in the size of right heart cham-
bers and normalization of intraventricular septal mo-
tion). Within a 24-month follow-up the majority of pa-
tients demonstrated improvement of physical capacity, 
especially those younger than 40 years of age. Exercise 
tolerance improved regardless of the baseline functional 
impairment.
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